商品编号


CHI-HF-21015M-C050



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

50 ?g

商品信息


More Information



Product Details



Synonyms

Interleukin-15



Product Type

Protein



Properties



Source/Host

CHO cells



Sequence

The extracellular domain of human IL-15 (aa 49-162) including mutations at Q149D and Q156D is fused to the N-terminus of the Fc region of human IgG1.



Crossreactivity

Human



BIOLOG
ical Activity

This mutant IL-15/Fc fusion protein specifically binds to the IL-15R, competitively inhibits IL-15-triggered cell proliferation, promotes transplant tolerance, does not activate the STAT-signaling pathway, and exerts a prolonged circulating half-life caused by the modified Fc domain.



Purity

≥98% (SDS-PAGE)



Endotoxin Content

<0.06eu mu;g="" protein="" (lal="" test;="" lonza).="">0.06eu>



Reconstitution

Reconstitute 50?g vial in 50?l sterile water.
Add 1X PBS to the desired protein concentration.



Formulation

Lyophilized from 0.2μm-filtered solution in PBS.



Other Product Data

NCBI reference NP_751914.1: IL-15 (human)



Declaration

Manufactured by Chimerigen.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Interleukin-15 (IL-15) has a broad spectrum of
BIOLOG
ical activities. It is crucial for the development, proliferation, survival and differentiation of multiple cells from both innate and adaptive immune systems. IL-15 up-regulation has a central role in the development of several autoimmune or chronic inflammatory disorders. Targeting IL-15 or its receptor may have a valuable impact on the treatment of immune-mediated diseases. IL-15 participates in the development of important immune antitumor mechanisms. It activates CD8(+) T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Rα, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines.


Product References

A Dual Action of Rheumatoid Arthritis Synovial Fibroblast IL-15 Expression on the Equilibrium between CD4+CD25+ Regulatory T Cells and CD4+CD25- Responder T Cells: M. Benito-Miguel, et al.; J. Immunol.
183,
8268 (2009)

IL-2/α-IL-2 complex treatment cannot be substituted for the adoptive transfer of regulatory T cells to promote bone marrow engraftment: B. Mahr, et al.; PLoS One
11,
e0146245 (2016)